Frits van Rhee
Professor
Also affiliated: University of North Carolina at Chapel Hill (2006–2013); Cedars-Sinai Medical Center (2010); Fox Chase Cancer Center (2006–2010); National Institutes of Health (1997–2001); The University of Texas MD Anderson Cancer Center (2006–2013); Central South University (2023); Emory University (2013); University of South Carolina (2000–2004); University of Basel (2005); Medical College of Wisconsin (2000–2024); Cornell University (2006–2013); University of Arkansas Medical Center (2005–2026); Anthony Nolan (2001–2002); Aberdeen Royal Infirmary (1995); The Royal Free Hospital (2002); Southmead Hospital (1995); Hammersmith Hospital (1995–2001); John Radcliffe Hospital (1992); Palmetto Health Richland (2000–2001); Centre Hospitalier Universitaire de Nantes (2010); Moffitt Cancer Center (2010); Blood Cancer UK (1994–2000); Massachusetts General Hospital (2022); Fred Hutch Cancer Center (2002–2013); Cancer Research And Biostatistics (2003–2015); National Heart, Lung, and Blood Institute (1997–2001); Queen Elizabeth Hospital (1990–2008); Hopp Children's Cancer Center Heidelberg (2022); Dana-Farber Cancer Institute (2003); Myeloma UK (2007); Little Flower Hospital & Research Centre (2023); Queen's Medical Centre (1991); Third Xiangya Hospital (2023); Xiangya Hospital Central South University (2023); Weill Cornell Medicine (2013); Winship Cancer Institute (2010); UNC Lineberger Comprehensive Cancer Center (2013); AbbVie Biotherapeutics (United States) (2009); University College London (2002); Imperial College London (1997–2001); University of Pennsylvania (2013); Ludwig-Maximilians-Universität München (1995); The University of Texas Southwestern Medical Center (2000)
Internal Med, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Dr. Frits van Rhee's research focuses on the immunotherapy of multiple myeloma and Castleman's Disease. He holds the Charles and Clydene Scharlau Chair for Hematological Malignancies Research at the University of Arkansas for Medical Sciences, where he also serves as Professor of Medicine and Director of Developmental and Translational Medicine within the Myeloma Institute for Research and Therapy.
His work has resulted in hundreds of manuscripts and abstracts, and he is recognized as a world-leading expert in Castleman's Disease. Dr. van Rhee's scholarship includes publications on the molecular classification of multiple myeloma, gene expression profiling, and the role of specific genetic alterations in disease progression and prognosis. He has also investigated therapeutic targets such as CS1 for multiple myeloma and explored the utility of imaging techniques like F18-fluorodeoxyglucose positron emission tomography in assessing prognostic factors.
Dr. van Rhee is a member of several professional societies, including the International Society for Experimental Hematology and the International Society for Cellular Therapy. He also contributes to the scientific community as an editorial review board member for journals such as Annals of Hematology and Bone Marrow Transplantation. His research network includes collaborations with colleagues at the University of Arkansas for Medical Sciences, such as Maurizio Zangari, Carolina Schinke, Sharmilan Thanendrarajan, and Samer Al Hadidi.
Research Overview
Dr. Frits van Rhee received his medical degree at Erasmus University, Rotterdam, Netherlands, and his PhD at the Imperial College of Science, Medicine and Technology, University of London. He trained in internal medicine and hematology in the UK, and in bone marrow transplantation (BMT) at Oxford and the Royal Postgraduate Medical School in London. Dr. van Rhee is a professor of medicine and director of developmental and translational medicine with the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences. He also holds the Charles and Clydene Scharlau Chair for Hematological Malignancies Research. Dr. van Rhee holds memberships in the International Society for Experimental Hematology, the International Society for Cellular Therapy, and the European Group for Bone and Marrow Transplantation. He serves on the editorial review boards for Annals of Hematology, Bone Marrow Transplantation, and Cytotherapy. He has written hundreds of manuscripts and abstracts, as well as presented at scientific meetings. Dr. van Rhee's current research focuses on immunotherapy for myeloma. Dr. van Rhee is also a world-leading expert in Castleman's Disease.PublicationsMake an appointment with the UAMS Myeloma Institute
Metrics
- h-index: 83
- Publications: 883
- Citations: 27,050
Positions
-
Section Chief 2001–presentUniversity of Arkansas for Medical Sciences Division of Hematology/Oncology Myeloma section ORCID
-
Professor publications 2001–2026University of Arkansas for Medical Sciences Internal Med, College of Medicine Institutional directory
Selected Publications
-
MM-224: Outcomes and Toxicity of CAR T-Cell Therapy in Patients With Renal Impairment: A Propensity Score-Matched Analysis in Relapsed/Refractory Multiple Myeloma (2026)
-
POSTER: MM-224: Outcomes and Toxicity of CAR T-Cell Therapy in Patients With Renal Impairment: A Propensity Score-Matched Analysis in Relapsed/Refractory Multiple Myeloma (2026)
-
POSTER: IBCL-492: Diagnostic Delays and Comparable Response Rates to iMCD-Directed Therapies in Patients With and Without Expert-Confirmed Idiopathic Multicentric Castleman Disease Diagnoses (2026)
-
IBCL-492: Diagnostic Delays and Comparable Response Rates to iMCD-Directed Therapies in Patients With and Without Expert-Confirmed Idiopathic Multicentric Castleman Disease Diagnoses (2026)
-
Testicular Plasmacytoma: A 25-Year Experience from a High-Volume Tertiary Center and Comparative Review of the Literature (2026)
-
Long term follow up of multiple myeloma patients achieving MRD negativity at 10 <sup>-6</sup> . (2026)
-
In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence. (2026)
-
Testicular plasmacytoma: A comprehensive case series and review. (2026)
-
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)
-
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)
-
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)
-
Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist’s perspective (2025)
-
Siltuximab-mediated suppression of CRP is associated with clinical response in idiopathic multicentric castleman disease (2025)
-
MM-1225: Comparison of Short-Term Outcomes and Safety Profile Between Daratumumab-Based Quadruplet Versus Triplet Induction Regimens for Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma: Meta-Analysis of Randomized Controlled Trials (2025)
Grants & Funding
As listed on this researcher's institutional profile.
- Qualitative Research in Castleman's Disease: Exploring Patients' Perspectives through Interviews, Project #A2-7438 United BioSource Corporation Principal Investigator
- UARK 2006-41 A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized anti-CS1 Monoclonal lgG1 antibody) in Subjects with Adva Protein Design Labs, Inc Principal Investigator
- UARK 2004-61: (AMD3100-3102) A Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240 ug/kg) plus G-CSF (10 ug/k AnorMED, Inc. Principal Investigator
- 2004-23: (Protocol C0328T03) A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Administered Biweekly as an Intravenous Infusion Centocor, Inc. Principal Investigator
- KAG 301-Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (Kos 953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Genzyme Principal Investigator
- UARK# 2012-02 TOTAL THERAPY 5B: A PHASE II TRIAL FOR HIGH-RISK MYELOMA EVALUATING Onyx Pharmaceuticals, Inc. Principal Investigator
- A Randomized, Double blind, Placebo controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportiv Centocor, Inc. Principal Investigator
- Protocol CNTO328MCD2002; Phase 2, An Open-label, Multicenter Study to Evaluate th Centocor, Inc. Principal Investigator
- UARK 2003-01, Stem Cell Mobilization and Transplantation of Proven and/or Predicted Poor Mobilizers with Mutliple Myeloma AnorMED, Inc. Principal Investigator
- S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct...260489 NIH/Nat. Cancer Institute via SouthWest Oncology Group Principal Investigator
- JAK1/2 as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target NIH/Nat. Heart, Lung & Blood Institute via University of Pennsylvania Principal Investigator
- KIR-Ligand Mismatched Natural Killer Cell Therapy for Myeloma Multiple Myeloma Research Foundation Principal Investigator
- Contribution of osteocytes to the musculoskeletal effects of Multiple Myeloma NIH Co-Investigator
- ACCELERATE: An Efficient and Innovative Natural History Study Addressing Unmet Needs in Castleman Disease Food & Drug Administration via University of Pennsylvania Medical Center Principal Investigator
- Polymorphism in Castleman’s Disease Janssen Research & Development, LLC Principal Investigator
- UARK 2003-41, A Phase II Study of High-Dose Density Therapy with Tandem Autologous Transplants for Patients with Multiple Myeloma Amgen, Inc. Principal Investigator
- UARK 2003-26, A Pilot Study of MAGE-3 and NY_ESO Immunotherapy in Combination with DT PACE Chemotherapy/Autologous Transplant in Agressive Mutliple My Celgene Principal Investigator
- UARK 2002-36, An Open Label, Phase I Extension Study to Assess the Long-Term Safety and Tolerability of MRA as a Treatment for Castleman’s Disease Chugai Biopharmaceuticals, Inc. Principal Investigator
- Potentiating Natural Killer Cell Anti-Myeloma Effects NIH Principal Investigator
- Engraftment Kinetics of Peripheral Blood Stem Cells (PBSC's) Isolated Using the Spectra Optia Apheresis System CaridianBCT Principal Investigator
- mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target NIH/Nat. Cancer Institute via University of Pennsylvania Principal Investigator
- A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to evaluate the Safety and Immunogenicity of the GSK Biologicals’ Herp GlaxoSmithKline Principal Investigator
- Phase 3 Study of Daratumumab, Bortezomib, Lenalidomide & Dexamethasone (D-VRd) + Ciltacabtagene Autoleucel vs D-VRd + Autologous Stem Cell Transplant in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients Stichting European Myeloma Network via PAREXEL International LLC Principal Investigator
- Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administered Intranodally in Multiple Myeloma Patients Leukemia & Lymphoma Society Principal Investigator
- Phase 3 Randomized, open-label clinical trial of tanespimycin (KO953) plus Bortezomib Compared to bortezomib alone in patients with multiple myeloma i Bristol-Meyers Squibb Principal Investigator
- mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target - Continuation NIH/Nat. Cancer Institute via University of Pennsylvania Principal Investigator
- 2004-04: Treatment with AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Giv AnorMED, Inc. Principal Investigator
Collaboration Network
Top Collaborators
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Showing 5 of 100 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
Showing 5 of 82 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
Showing 5 of 56 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Showing 5 of 54 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
Showing 5 of 51 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
Showing 5 of 48 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Showing 5 of 41 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Showing 5 of 38 shared publications
- Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
- Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
- Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3
- Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
- Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma
Showing 5 of 36 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Showing 5 of 33 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Showing 5 of 31 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Curing myeloma at last: defining criteria and providing the evidence
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
Showing 5 of 31 shared publications
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Perspectives on the Treatment of Multiple Myeloma
Showing 5 of 25 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
- Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
Showing 5 of 22 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
- Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
Showing 5 of 22 shared publications
Similar Researchers
Based on overlapping research topics